FindTrial
Sign In

Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00239252
Enrollment
Unknown
Registered
2005-10-17
Start date
Unknown
Completion date
Unknown
Last updated
2014-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Keywords

Interferon alfacon-1, Virus disease, Hepatitis C

Brief summary

Efficacy and safety is compared between interferon alfacon-1 alone and concomitant dosing of interferon alfacon-1 and ribavirin in hepatitis C patients.

Interventions

DRUGInterferon alfacon-1

Sponsors

Schering-Plough
CollaboratorINDUSTRY
Astellas Pharma Inc
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Hepatitis C patients (high titer, genotype1)

Exclusion criteria

* Patients with autoimmune disorder * Patients with negative HBs antigen * Patients with hepatic cirrhosis, hepatic failure and hepatic cancer * Patients with depression or psychoneurotic disorder

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026